As artificial intelligence reshapes the competitive landscape, tech leaders face a stark choice: disrupt their own profitable core businesses or risk being left behind. New financial results from Microsoft, Meta, and Tesla reveal the high-stakes strategies—and market reactions—defining this pivotal moment.
Citi has updated its model for GlobalFoundries, lifting the price target to $42 and extending its valuation horizon to 2027. The move follows the chipmaker's strategic acquisition of Synopsys' ARC Processor IP business, aimed at accelerating its physical AI roadmap.
Ovid Therapeutics (NASDAQ: OVID) has garnered analyst optimism following positive Phase 1 trial results for its novel neurological drug candidate and a recent 'Outperform' initiation. The biotech firm is now shifting focus to a more potent oral therapy, with key regulatory milestones ahead.
Michigan's Attorney General has formally demanded the return of state funds from Gotion Inc., a Chinese battery manufacturer, following the collapse of its planned $2.4 billion facility. The move highlights growing tensions over foreign investment in U.S. strategic industries.
Reed Jobs, son of the late Apple co-founder Steve Jobs, has secured over $200 million for Yosemite, a venture fund dedicated to pioneering cancer treatments. Backed by major institutions, the fund seeks to transform cancer from a fatal diagnosis to a chronic, manageable disease within a generation.
As SpaceX reportedly engages banks for a potential 2026 public offering, the pre-IPO secondary market for late-stage tech giants is booming, offering a critical liquidity valve and reshaping the path to going public.
A trove of documents released by the U.S. Department of Justice includes emails from Jeffrey Epstein making lurid, unsubstantiated allegations about Bill Gates, while also detailing his interactions with other prominent individuals.
Thermo Fisher Scientific posted stronger-than-expected Q4 revenue and profit, driven by new products and strategic deals. However, the stock fell as investors weighed pressures in key academic and government markets against the company's solid 2026 outlook.
Robust cash generation is a hallmark of financial health, but it doesn't guarantee future performance. We examine three companies with strong free cash flow margins whose underlying challenges—from competitive pressures to growth concerns—suggest investors should look closer before buying.
Profitability alone is no longer a reliable indicator of future success. In today's competitive landscape, companies must balance healthy margins with sustainable growth. We analyze one firm positioned to do just that, and two where investors should look deeper.
The third-quarter earnings season reveals a sector at a crossroads. While government and technical consulting firms like Jacobs Solutions benefit from long-term structural trends, their latest financial results and market reactions paint a complex picture of resilience and recalibration.
Insulet Corp (PODD) has emerged as a top pick among hedge funds in the medical device sector, buoyed by overwhelmingly bullish analyst ratings and a price target suggesting significant growth potential. The company's innovative tubeless insulin pump system is seen as a key driver.
Driven by falling costs and strong incentives, heavy manufacturing is increasingly turning to on-site solar power. This shift is transforming large factory roofs from passive structures into strategic assets for cutting energy bills and emissions.
Fueled by surging global demand for its Hoka and Ugg brands, Deckers Outdoor Corp. posted a robust third-quarter performance that surpassed expectations, driving its stock price up sharply and assuaging recent Wall Street concerns over growth sustainability.
SLB has won significant five-year contracts from Petroleum Development Oman for the giant Block-6 field. The deals mandate local wellhead manufacturing and deploy advanced recovery technologies, anchoring SLB's long-term service role and supporting Omani job creation.
Novo Nordisk charts a bold new course, launching a pivotal oral obesity drug while restructuring its workforce and deepening its investment in next-generation cell therapies for metabolic diseases.
Cavco Industries reported a 21% year-over-year revenue increase to $508.4 million for fiscal Q4 2025, driven by a 28.5% surge in home shipments. Despite February weather disruptions and ongoing economic uncertainty, the manufactured housing leader saw a strong March rebound, executed a $33 million stock buyback, and launched a company-wide rebranding initiative aimed at simplifying the homebuyer journey.
The U.S. Department of Justice has initiated a civil rights investigation into the fatal shooting of Alex Pretti by federal immigration officers in Minneapolis, a senior official confirmed Friday. The probe could lead to criminal charges, though legal hurdles remain high.
Salesforce secures a potential 10-year, $5.6 billion IDIQ contract with the U.S. Army, a strategic win for its national security unit. Yet, analysts caution the headline figure is a ceiling, not a guarantee, with real value hinging on future task orders and AI integration.
The doughnut giant has agreed to a multimillion-dollar settlement following a 2024 cyberattack that compromised personal data of current and former staff, though it admits no fault.
